Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Light Bio Inc. currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. This level of activity shows that the company is actively pursuing patent protection for its biological innovations. The 3 pending actions represent the current workload as the company seeks to move its applications through the examination process.
The company's prosecution involves 3 distinct examiners and 2 distinct art units. This distribution suggests that the 3 pending office actions are technically related enough to fall within only 2 art units, yet they are being reviewed by 3 different individuals. This scenario requires the company to manage 3 separate examiner relationships while also considering the broader policies of the 2 art units involved. The use of 3 distinct examiners provides a variety of viewpoints on the company's patent claims.
LOUNTOS, GEORGE THEMISTOCLIS is the busiest examiner for Light Bio Inc., with 1 pending office action. Since each of the 3 pending office actions is handled by a different examiner, LOUNTOS, GEORGE THEMISTOCLIS shares the workload equally with the others. The company's prosecution strategy must be flexible enough to respond to the unique requirements of each of the 3 distinct examiners. Understanding the specific tendencies of LOUNTOS, GEORGE THEMISTOCLIS and the other examiners is key to a successful outcome.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LOUNTOS, GEORGE THEMISTOCLIS | 1 | 57.1% | +60.0% |
| JOHNSON, EMILY KATHARINE | 1 | 87.5% | +21.9% |
| ROBINSON, HOPE A | 1 | 67.7% | +43.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18415180 | NOVEL LUCIFERASES AND METHODS FOR USING SAME | JOHNSON, EMILY KATHARINE | 60d overdue |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18816641 | MODIFIED BIOLUMINESCENT ENZYMES | LOUNTOS, GEORGE THEMISTOCLIS | — |
| 18244763 | ENZYMES OF LUCIFERIN BIOSYNTHESIS AND USE THEREOF | ROBINSON, HOPE A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18415180 | NOVEL LUCIFERASES AND METHODS FOR USING SAME | JOHNSON, EMILY KATHARINE | 60d overdue |
| 18816641 | MODIFIED BIOLUMINESCENT ENZYMES | LOUNTOS, GEORGE THEMISTOCLIS | — |
| 18244763 | ENZYMES OF LUCIFERIN BIOSYNTHESIS AND USE THEREOF | ROBINSON, HOPE A | — |
| Art Unit | Apps |
|---|---|
| 1652 | 2 |
| 1662 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18816641 | MODIFIED BIOLUMINESCENT ENZYMES | LOUNTOS, GEORGE THEMISTOCLIS | 1652 | §103§112 | Non-Final OA | — | Pending | Aug 27, 2024 |
| 18415180 | NOVEL LUCIFERASES AND METHODS FOR USING SAME | JOHNSON, EMILY KATHARINE | 1662 | §112 | Non-Final OA | 60d overdue | Pending | Jan 17, 2024 |
| 18244763 | ENZYMES OF LUCIFERIN BIOSYNTHESIS AND USE THEREOF | ROBINSON, HOPE A | 1652 | §101§102§112 | Non-Final OA | — | Pending | Sep 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLight Bio Inc. has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
George Themistoclis Lountos has the most, with 1 of Light Bio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
